Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 17/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6394832 | 0.79 | BRD4 (0.36) | APPMAPTTSHR | |
| SCHEMBL9718812 | 0.78 | HPGD (0.38) | MEN1KMT2A | |
| SCHEMBL10568742 | 0.78 | SMN1; SMN2 (0.56) | MAPTTSHRMEN1GAAKMT2A | |
| SCHEMBL5918903 | 0.74 | IDO1 (0.31) | — | |
| SCHEMBL499291 | 0.74 | ESR1 (0.42) | APPMAPTMEN1GAAKMT2A | |
| SCHEMBL9718839 | 0.74 | CYP1A2 (0.36) | GAA | |
| SCHEMBL3424113 | 0.74 | ALDH1A1 (0.42) | KIF11APPMAPTMEN1GLA | |
| SCHEMBL1680192 | 0.73 | ME2 (0.43) | APPMAPTMEN1KMT2ACA12 | |
| SCHEMBL9429404 | 0.73 | RAB9A (0.37) | KIF11MAPTMEN1KMT2A | |
| SCHEMBL7241026 | 0.72 | TSHR (0.49) | MAPTTSHRMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130189347-A1 | DISEASE TREATMENT DRUG | YUASA MAKOTO (JP) | 2013-07-25 | — | — | US | disclosed |
| EP-2601954-A1 | THERAPEUTIC AGENT FOR DISEASE | Yuasa, Makoto (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-20050008687-A1 | Metal-porphyrin-complex-embedded liposomes, production process thereof, and medicines making use of the same | MAKOTO YUASA (JP) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189347-A1 | DISEASE TREATMENT DRUG | PPOX, TFRC, SLC40A1 | KIF11 3226/4885APP 2724/4885MAPT 500/4885 |
| US-20050008687-A1 | Metal-porphyrin-complex-embedded liposomes, production process thereof, and medicines making use of the same | GPX4, FECH, PPOX | KIF11 3943/4885APP 1458/4885MAPT 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.